Eribulin mesylate (Halaven) is approved for use by women with locally advanced or metastatic breast cancer whose disease has progressed despite previous drug treatment. The IQWiG  has checked whether the drug in these patient groups compared with the appropriate comparator therapy provides additional benefit.

Accordingly, there are both positive and negative effects. In a group of patients, there is proof of a little added value. For other groups, there is evidence of a lower benefit.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/eribulin-bei-brustkrebs-bei-bestimmten-patientinnen-uberwiegen-positive-effekte-bei-anderen-negative.6407.html?&et_cid=4&et_lid=%25208 [German]